3 criteria have to be fulfilled by an invention to receive patent protection for 20 years: inventive step, industrial application, novelty. User Rights With a patent in place, user rights can be clearly defined and licensed. Teaming up with governmental institutions, organizations and academic scientist becomes easier. A big help when researching new treatments for unmet medical needs. National authorities It depends on the date of application and the regulations of national authorities when and for how long the patent is valid. Once approved the Orphan Drug Status allows inventors to keep sales rights exclusive for a little longer. An exception to reduce the financial risk and encourage the work on treatments for rare disorders. The length of protection depends on the country and region. www.pharma.bayer.com
Views: 2365 Bayer Pharmaceuticals
Overview of general marketing in the pharmaceutical industry: product positioning and competitive analysis, with a brief glance into the AED market (Philips & ZOLL). Pharma marketing in a digital landscape - 0:27 Our market is the most competitive market? - 0:45 Product positioning and competition in a saturated market - 1:11 Product differentiation & market segmentation - 1:31 What do you do after launch? (lifecycle management) - 2:50 Transcript: https://pharmadigitalmarketing.com/marketing-in-pharma/ Site: https://pharmadigitalmarketing.com
Views: 5995 Pharma Digital Marketing
In this interview with Prof. R. Srinivasan, faculty in the Corporate Strategy and Policy department at IIM Bangalore, who has studied the pharmaceutical sector in India, we try to understand the Indian pharmaceutical industry in terms of its evolution, changes in strategy, merger and acquisition activities, growth prospects and future trends.
Views: 480 tejasvideochannel
Click here for more Information: https://www.audioeducator.com/pharma-biotech/anda-paragraph-iv-patent-certifications-07-06-2016.html Regulatory Requirements for ANDAs and Paragraph IV Patent Certifications Presented By: David Lim This session with expert David Lim will discuss the regulatory requirements for generic drug applications, and in particular, will cover patent certifications (paragraphs 1-4) with major focus on Paragraph IV certifications. David will help you better understand regulatory requirements for ANDA filings with focus on paragraph IV (para IV) certifications. More Videos: - http://www.youtube.com/user/audioeducator2 You can also connect with us on Twitter, Facebook, Google+ and LinkedIn and get the most updated news and views, expert advice and tips to help resolve your coding, billing & compliance dilemmas quickly and accurately. Connect with us on Twitter: - https://twitter.com/audioeducator Facebook: - https://www.facebook.com/pages/AudioEducator/244912592201260 LinkedIn: - http://www.linkedin.com/company/audio-educator Google+: - https://plus.google.com/102668946943256059069/posts
Views: 2370 AudioEducator
The importance of the Indian Supreme Court's decision on generic drugs, why the bar is lower for generic drug production in the United States,why Pharma companies drive inefficiency and threaten global health, why pharma companies are primarily marketing firms , why medicine is a "Global Public Good" and why "free trade agreements" are simply a giveaway for corporations... This clip from the Majority Report, live M-F at 12 noon EST and via daily podcast at http://Majority.FM Subscribe to us on YouTube: http://youtube.com/user/SamSeder
Views: 1337 The Majority Report w/ Sam Seder
This was a presentation I made for one of my IP courses in law school at Berkeley Law, Fall 2016. This is just a basic overview of strategies used by pharmaceutical manufacturers (patent holders) for protecting their patent rights and exploiting them as best they can, as well as the basic process for generic market entry.
Views: 753 Matt Kempf
Do you want to know more about Patenting of Pharmaceuticals? Here in this video Mr. Biswajit Sarkar (Owner at Biswajit Sarkar - Advocates - IP Attorneys), is giving speech on patent strategies, issues and concerns for medical device inventions and about pharmaceutical patent law in India. You can understand what is the role of patent in pharmaceutical industry in India and why are drug patents important in this video.
This lecture is a part of a NPTEL course on Patent Law for Engineers and Scientists. Course link for January-April 2018— https://onlinecourses.nptel.ac.in/noc18_hs20/preview Course forum for January-April 2018— https://onlinecourses.nptel.ac.in/noc18_hs20/forum The above links can be only accessed if you have registered for the course. However, you can always follow our social media channels here— Facebook Page— https://www.facebook.com/LexCampus/ YouTube Page— https://www.youtube.com/lexcampus You can download our Patent drafting workbook here— https://goo.gl/edtPPp
Views: 1015 Patent Law for Engineers and Scientists
12 Hour MBA in Pharma The 12 Hour MBA in Pharma is an entry-level course designed to bridge knowledge gaps. It is most useful to new entrants, senior managers needing a big picture refresher and professional advisors to the sector. Explore real-world lessons they don't teach you on the job, from the comfort of your desk. In just 12 hours you will: - Understand the scope and scale of the pharmaceutical industry - Learn where value is created - Follow a drug from molecule to profitable market - Appreciate the constraints and requirements of the regulated healthcare marketplace - Understand how drugs are promoted - Be able to create a financial map of a typical pharmaceutical product launch - Evaluate pharmaceutical company value drivers - Have considered where the pharmaceutical industry is likely to go in the face of limited budgets and aging populations For more information: http://www.terrapinntraining.com/training/12-Hour-MBA-in-Pharma
Views: 287 TerrapinnTraining
Pharmaceutical patent protection is extremely important. Only by achieving secure protection with pharmaceutical patents can the huge investment necessary to bring a pharmaceutical product to market be safeguarded and an adequate return on that investment realised. In this video our specialist pharmaceutical patent attorneys talk about some of the key aspects of intellectual property (IP) for the pharmaceutical and chemistry industry.
Views: 40 Adamson Jones
Patents and exclusivity work in a similar fashion but are distinctly different from one another. Patents are granted by the patent and trademark office anywhere along the development lifeline of a drug and can encompass a wide range of claims. Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met. Exclusivity was designed to promote a balance between new drug innovation and generic drug competition. [vpdrugs]
Views: 8982 USFoodandDrugAdmin
Indian Pharmaceutical Patent Lawyer for Research* Patent protection effectively grants pharmaceutical industry a monopoly, regardless of the human consequences Chemical patent, pharmaceutical patent or drug patent is a patent for an invention in the chemical or pharmaceuticals industry. Drug Patents and Generic Pharmaceutical Drugs. When a pharmaceutical company first develops a new drug to be used for a disease condition, it is initially sold under a brand name by which the clinicians can prescribe the drug for use by patients. Patents protect drugs from copycat versions for 20 years after the drug is invented.
By exploiting the patent system to keep generic drugs off the market, Big Pharma makes lifesaving medicines unaffordable to many in need. Tahir Amin, co-director of the Initiative for Medicines, Access, and Knowledge, explains how it works, and what his group is doing to stop it. Learn more: http://www.opensocietyfoundations.org/topics/access-medicines
Views: 4428 Open Society Foundations
Guests: Dr. Gopa Kumar Nair (Chairman, Sub Committee on Intellectual Property Rights of the Indian Drug Manufacturers Association) ; Dr. C M Gulati (Editor , Monthly Index of Medical Specialties (MIMS) and a drug expert) ; Nilotpal Basu (Central Committee Member, CPI(M) and former MP) Anchor: Girish Nikam
Views: 1422 Rajya Sabha TV
Decades after Dr. Jonas Salk opposed patenting the polio vaccine, the pharmaceutical industry has changed. What does that mean for the development of innovative drugs and for people whose lives depend on them? More videos from Retro Report: http://www.retroreport.org Like Retro Report on Facebook: http://fb.com/RetroReport Follow Retro Report on Twitter: http://twitter.com/RetroReport Follow Retro Report on Instagram: https://instagram.com/retroreport/
Views: 14955 RETRO REPORT
Patent pending product, efficient treatment for Aphthous (mouth ulcers). Product is patent pending and property of Tree of Life Pharma Ltd. The movie clip was created by Andy Henik: alio3d - Animation and Video Editing
Views: 27 Andy Henik
You can mail us at [email protected] & [email protected] for more details. Patenting of Pharmaceutical Patent Law in India https://www.linkedin.com/in/patentindiaiplawpritykhastgir/ India is considered as a leading exporter and holds second position in export of generic drugs in terms of volumes. Balance the law by development of the Pharmaceutical Sector in India and for regulating the issues related to pricing and availability of medicines in India. Prity specialises in intellectual property issues relating to pharmaceutical and international biotechnology companies. Ask your Patent and Intellectual Property queries by using hashtag #askpatentexpert on twitter. #business #innovation #technology #bigdata #AI #ML #AugmentedReality #VirtualReality #Chatbots
Influence of Product Patents on Indian Pharma Industry 2013 İNDİA
Views: 89 mehmet celikoll
By reforming harmful supranational regulations, Thomas Pogge is developing a complement to the patent system to stimulate pharmaceutical innovations that would be accessible, without delay, to poor and affluent patients alike around the world. In this talk at TEDxCanberra 2011, ANU and Yale academic and ethicist, Professor Thomas Pogge outlines an idea that could revolutionise health outcomes and distribution of pharmaceuticals in both the developed and developing world. In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations).
Views: 73568 TEDx Talks
Marie Manley shares her experiences of working in the pharmaceutical industry and offers her perspectives on advising pharmaceutical companies, and cross-referring to other areas of law. https://global.oup.com/academic/product/navigating-european-pharmaceutical-law-9780198717997 MARIE MANLEY is a Partner at Bristows in London, a law firm specialised in advising technology clients, and head of the Regulatory Department. She advises on IP matters (both contentious and non-contentious), focusing on European and UK regulatory and competition law in the bio-pharma, chemical, cosmetic, medical devices and food sectors; including life cycle management issues, advertising and product liability. © Oxford University Press
Views: 291 Oxford Academic (Oxford University Press)
Access to medicines patents can be a question of life and death in the developing world. Global discussions have centred on how to prevent the "tragedy of the anti-commons," in which use of important drugs is off-limits due to the intellectual property rights while also preserving incentives to innovate. The Medicines Patent Pool is an initiative that goes beyond the discussion clearing away medicines patent barriers to increase access to new, affordable HIV treatment in developing countries. Ellen 't Hoen is an independent medicines law and policy consultant. She has particular expertise in the area of access to medicines and intellectual property. Her most recent achievement is the establishment of the Medicines Patent Pool to accelerate the availability of low cost HIV treatments in developing countries through patent licensing. In 1981 she co-founded DES Action the Netherlands and remained its coordinator until 1990. In 1990 she joined Health Action International to head the policy and campaigns unit. From 1996 until 1999 she was the international coordinator of the independent medicines journal La Revue Prescrire/Prescrire International and the International Society of Drug Bulletins (ISDB). From 1999 until 2009 she was the Director of Policy and Advocacy at Médecins sans Frontières' (MSF) Campaign for Access to Essential Medicines. In 2009 she became the Senior Adviser for Intellectual Property and Medicines Patent Pool at WHO/UNITAID where she set up the Medicines Patent Pool which aims at brokering and making available patent licenses to antiretroviral medicines with the purpose of increasing access to low-cost and better adapted ARVs, for example pediatric formulations or fixed dose formulations for use in low and middle income countries. She was the executive-director of the Medicines Patent Pool until June 2012. She won several awards for her work on the effects of exposure to the drug (DES) in the 1980s and 1990s, including the prestigious Harriet Freezerring award in 1989. In 2005, 2006 and 2010 she was listed as one of the 50 most influential people in intellectual property in the world by the journal Managing Intellectual Property. She is a research fellow at the IS HIV/AIDS Academy of the University of Amsterdam and authored the book "The Global Politics of Pharmaceutical Monopoly Power. Drug patents, access, innovation and the application of the WTO Doha Declaration on TRIPS and Public Health." which was published in January 2009 and is available for free download here: http://www.msfaccess.org/content/global-politics-pharmaceutical-monopoly-power. She is a member of the World Health Organization's Expert Advisory Panel on Drug Policies and Management and a member of the advisory board of Universities Allied for Essential Medicines (UAEM). In the spirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations)
Views: 25907 TEDx Talks
http://www.globalchange.com Lack of drug innovation and empty pharmaceutical product pipeline. Generic manufacturer pharma competition and product recalls. Patent expiry and intellectual property protection. Legal challenges and research scandals. Biogenerics and large molecule therapeutics. Cellular mechanisms of disease. Unmet health care needs. Government purchasing policies and health insurance cover. Online pharmacy price pressures. Search for new health care treatment blockbusters. Chronic disease and orphan drug therapies. Rheumatoid arthritis and asthma. Search for new antibiotics and multiple resistance infection problems. Search for powerful antiviral therapy. Future health funding and ageing populations. Contrast with emerging nations. Health treatment access and health injustice issues. Pharmacogenomics and gene prophecy. Ethical issues in gene therapy. HIV and AIDS search for treatments, cure and vaccine. Patrick Dixon, conference keynote speaker and futurist.
Views: 15003 Futurist Keynote Speaker Patrick Dixon - FUTURE
What does digital transformation mean for drug companies? Milind Kamkolkar, Chief Data Officer at Sanofi, speaks with CXOTalk co-hosts Richie Etwaru and Michael Krigsman about innovation and changes in the pharmaceutical industry. For more, see https://www.cxotalk.com/episode/digital-transformation-pharmaceutical-industry-innovation Sanofi is a company focused on empowering lives through human health. As CDO, Kamkolkar focuses on driving and transforming Sanofi from data generation to an insights generating organization where data is a monetizable asset class on par with product and shareholder value. Kamkolkar is also a featured speaker and thought leader in Digital Health, AI & Big Data; Honorary Lecturer for physician entrepreneurship at BartsX; Faculty at Exponential Medicine; and Special Advisor to the UN Global Sustainability program. Etwaru is Chief Digital Officer at QuintilesIMS, helping bridge the innovation and efficiency gap for healthcare stakeholders and life sciences customers using analytics and technology. He’s a former CDO at IMS Health, a frequent keynote speaker at leading tech-related events and forums, a serial entrepreneur, an author, a former Clinton Global Initiative delegate, and currently serves as a board member for multiple not-for-profit organizations. From the transcript: Michael Krigsman: (05:00) What are we actually speaking about and how does this relate to the broader changes that are going on regarding healthcare and ultimately, the impact on healthcare for people? For patients? Richie Etwaru: (05:24) Well, I think most of us understand siloes pretty well, right? These are vertical departments within large companies that tend to perform a specific function. And then they perform that function well, but if you look at multiple of those siloes together as a broad organization, you’ll see inconsistencies and gaps to be solved for. I think, with the pharmaceutical industry, there was a time when it was okay to have siloes. Not that you wanted them, but if you had them, it was not the biggest deal in the world, and we’re seeing what I like to call the “three waves” of change enter the environment of the pharmaceutical industry that’s creating the financial reality and quite frankly, the competitive reality, to start to think about what the business model looks like and take the siloes out. These three waves, I think, most people would recognize. (06:15) Now, the first wave is what came from the supply side. So, I think of this as the patent cliff, right? I think we’ve heard enough about the patent cliff that the supply of discovery of drugs in the pipeline has changed quite a bit. And, the good thing about the patent cliff is that it was sort of contained within the pharmaceutical industry, right? Yes, there was some implication too of the stakeholders, but it didn’t radically change the landscape because each pharma company was suffering from the same strain from a supply side. (06:47) The second wave is what I like to call the wave coming from the demand side. This is the influence and the pressures of reimbursement being changed, payment terms being changed. I think what we see in the United States with Obamacare and the model of delivery has created a tremendous amount of strain that created a whole new wave of pressures for the pharmaceutical industry. So, I think that’s the second wave. (07:18) Where we are today is what I like to call the “third wave” of change that’s coming through the pharma industry. And, this is the digital health and technology paradigms that are entering at the same time. Now, the patent cliff is not completely solved for. That's still moving over, right? The changes in the […] are not completely solved for. That's still here. And, we have this new wave that's being driven by this new stuff that Milind is talking about, which is more data, digital health, some of the new technology paradigms. What's interesting about this third wave is that it is not self-contained in the pharma industry or healthcare. Milind Kamkolkar: (14:46) Yeah. I mean, if I could just add one last thing, Michael, to that point, I think where the time, perhaps has that risk-averse nature in the pharmaceutical industry is that perhaps I’m like… banking in other such industries… The reality is that if you get this wrong, people die, right? And that’s the real crux of it. So, I can fully appreciate and respect the fact that sometimes, you do want to be a little bit cautious because, of course, who wants to create a medicine or some kind of patient service that really is not yielding a positive outcome? (15:19) So for one, I'm quite grateful for the fact that we are basing more medication and pricing, and reimbursements, etc. really on health outcomes. But I think, in many ways, it's not just the actual medicine that has to take into play, it's also the customer experience at point of treatment that needs to be part of that equation as well.
Views: 11679 CXOTALK
University of Virginia School of Law professor Margo Bagley delivers her lecture, 'Thou Shalt Not Steal': The Morality of Limits on Pharmaceutical Patents," to mark her appointment as Hardy Cross Dillard Professor of Law. (University of Virginia School of Law, Feb. 23, 2015)
Views: 630 University of Virginia School of Law
In this video, Elad Kedar of Orasis Pharmaceuticals and Finnegan attorney Jennifer Swan discuss current patent trends in the pharmaceutical industry. Pharmaceutical patents are becoming more difficult to pursue due to recent questions about what constitutes patentable subject matter within the biopharm space. Whether your company is a startup or a large company, when pursuing a pharmaceutical patent, it can be valuable to gain the perspective of an experience pharmaceutical patent litigator when building your claims. This video is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This video is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.
Alarming rates of new drug failures and sparse drug development pipelines of pharmaceutical industry, left behind by the genetic era of medical research, call for new approaches and reliable tests of cell function. New drug targets need to be validated using detained analyses and understanding of the metabolic network.
Views: 312 HirshbergFoundation
As pharmaceutical giants Novartis and Bayer challenge India's drug-patent rules, our correspondents discuss the potential implications for health care in the developing world Subscribe NOW to The Economist: http://econ.st/1Fsu2Vj Get more The Economist Follow us: https://twitter.com/TheEconomist Like us: https://www.facebook.com/TheEconomist View photos: https://instagram.com/theeconomist/ The Economist videos give authoritative insight and opinion on international news, politics, business, finance, science, technology and the connections between them.
Views: 43201 The Economist
Newsclick discusses with Dr. Amit Sengupta the impact of the recent Supreme Court judgement in the Novartis case on the Indian pharmaceutical sector, the Public Health Policy in the country and the R&D policies of foreign pharmaceutical manufacturers.
Views: 386 NewsClickin
Big Pharma has consistently created market monopolies at the expense of patients’ health and pocketbooks. The IPR process is one way to stop Big Pharma and provide low-cost generic medicines to patients. Learn more: http://www.StopRxPatentAbuse.com
Views: 33085 Association for Accessible Medicines
http://www.tve.org For over a decade, India has been the powerhouse behind low cost drugs for the developing world, especially Africa and Asia. India's $4.5 billion pharmaceutical industry is now at a crossroads following a new law introduced in January 2005. It's opened a highly charged debate, with opinion split right down the middle. Life has been to India to investigate. Poor families benefited from India's historic 1970 drug Patent Law, which granted patents on the process rather than the product. This means drug companies in India could produce medicines that had been researched and introduced by international firms simply by a slight change in the process. They could sell them at half the price but still make big profits. Dr. Y. K. Hamied, head of CIPLA, a generic drug company, says the new law will undermine the production of low cost drugs and people will die as a result. "What did Indira Gandhi say in 1981 at the WHO? That there should be no patenting of life and death. And that medicines should be free of patents. She said that in '81. Why isn't the government of India following her ideals today?" http://www.facebook.com/tveinspirechange
Views: 606 tveInspiringChange
http://www.euronews.com/ India's Supreme Court has rejected a request by Swiss drug-maker Novartis to patent an updated version of its cancer drug Glivec. Glivec costs around 2,000 euros per month whereas the domestically produced generic equivalent costs around 140 euros. The judgement is supported by healthcare activists who want the government to make medicines cheaper. Neena Manghaney from Médecins Sans Frontières (Doctors Without Borders) said: "It's hugely significant because eight million people with HIV are on treatment from India more than 80 percent of these people get these drugs from India. In the area of HIV, this decision is path breaking. Number 2 is this: By protecting generic competition and abusive practices of pharma companies like Novartis, I think the Supreme Court has safeguarded the rights of patients across the developing world." The ruling is a blow to Western firms who are increasingly focusing on India to drive sales. Pratibha Singh, an advocate for Indian drug-makers, said there is no ambiguity in the Supreme Court's decision: "One implication is clear that the Indian provision, Section 3d has been completely upheld ,No1?No2, patent would be granted only for genuine inventions and repetitive patenting will not be allowed." This case is a benchmark for several intellectual property disputes in India, where patent drugs are unaffordable for most of its 1.2 billion people, 40 percent of whom live on less than a euro per day. Find us on: Youtube http://bit.ly/zr3upY Facebook http://www.facebook.com/euronews.fans Twitter http://twitter.com/euronews
Views: 4681 euronews (in English)
World’s leading life science patent litigation law firm: Full patent service firm providing range of patent application preparation and prosecution services in India & International Patent Filing Services. https://startupindiastrategist.com We have many professionals with advanced degrees in chemistry and the life sciences. Our attorneys and patent agents have drafted and prosecuted applications for small molecule pharmaceuticals, biopharmaceuticals, bioinformatics, personalized medicine, polymorphs, pharmaceutical formulations, methods of treatment, methods of manufacture, and diagnostic methods. We can also assist you in obtaining patent term extensions for patent office and regulatory agency delays through our team of global patent attorneys. Pharmaceutical Patent Law Firm Lawyer in India #druglawyer #askpatentexpert
the Indian pharmaceutical industry has been strongly supported by government of India. India signed the Trade Related Intellectual Property Argument in 1995 saying that country will implement a stronger product patent recognizing regime from 2005. From 1970 to 2005, there was actually a regime in the country that only recognized process patents, gave shorter patent life-term, which basically engendered the formation of these reverse-engineering skills of the Ciplas and the Reddys that I was just talking about. Since 2005, India has become TRIPS and product patent compliant like all other developed economies, but there is a particular provision that continues to raise debates. This particular provision is called the article 3D. Article 3D is about whether you are going to be allowed a patent if you are doing incremental innovation. If you have a drug like Imatinib Mesylate which is Novartis's active ingredient for the drug called Gleevec, and Imatinib Mesylate turns out to be just an incremental innovation of some original drug, the Indian new patent laws wouldn't allow Novartis the patent for that particular drug invoking the provisions of article 3D. And this became a huge debate in about three years back when Gleevec after like a protracted legal battle with the Indian government didn't get patent on this particular product and global stakeholder started raising a hue and cry that the government was actually not respecting product patents. They might have signed it, they might have implemented it but using the 3D provision, they were basically trying to retain that older regime of process-patents but that might not be true. There are several recent examples where the courts of India have actually allowed product patent respecting drug from a western pharmaceutical firm to be sold and barring the generic version of the drugs to be sold in the country. One case in point, very recently over the last few weeks, has been that of Sitagliptin, which basically is a drug from Merck, under the brand name Januvia. It is a new advanced-generation, oral anti-diabetic drug and it got an injunction from the Supreme Court of India which barred Indian pharmaceutical firm Glenmark in terms of selling the generic version of the drug. So, broadly speaking this tussle between access versus innovation continues. 3D continues to be invoked by either the government and the regulator in terms of not granting patents or being stringent about granting patents to originator firms. The Indian generic industry continues to heavily rely on sales from generic medicines, both domestically and exports, to generate the returns that it requires to deliver to its shareholders. But at the same time you start wondering if there is a middle ground that can be struck. There are a few middle grounds that global economists and scholars in this area have suggested. Let me just deliberate on them one by one. First, the global originator firms have backtracked a bit. They have started discussing that maybe we shouldn't sell drugs at the monopoly prices that are afforded to us given the intellectual property rights. Maybe we should sell it at differentially priced levels which is some fraction of the levels at which these drugs are being sold in developed countries. Januvia, the example I mentioned, is one such case. Second, Indian pharmaceutical firms themselves are becoming a little more conscious, especially those at the frontier in not infringing patents of alternative firms. In fact, they themselves are getting into the innovation space and are filing patents for drugs that they are discovering. The old history of not being able to take Balaglitazone to success that we saw with Dr. Reddy's probably is getting slowly changed. You have lipaglyn from Zydus Cadila in Ahmedabad, which has been filed with a new chemical entity in the U.S. FDA. You have Latanoprost from Sun Pharmaceuticals and its research company Sun Pharmaceuticals Advanced Research Center that recently got a complete request from the U.S. food and drug administration. And you have ALZUMAb a psoriasis drug from Biocon who has also filed a new patent for this particular therapeutic market. So, for verdict is still not out in terms of what will happen, there are some middle grounds that are being struck in terms of firm responses and reactions. The other aspect here that regulators are contemplating on is perhaps there could be alternative mechanisms to incentivize innovation other than intellectual property and here you could try to run into classifying therapeutic market and diseases of the world under the broader rich versus poor diseases or the shivering and the shimmering kind of diseases. So, Yale economist Thomas Pogge argues that maybe you can create something called the Health Impact Fund that incentivizes innovation in those particular disease markets where there is a need for rapid innovation and where there is a need to protect that innovation through intellectual property.
Views: 118 Gaurav Kumar Sharma
Davy chief economist Conall MacCoille discusses the overstated importance of the pharma sector in the Irish economy.
Views: 158 DavyGroup
be creativo Subscribe today and give the gift of knowledge to yourself or a friend Looking Ahead: Pharma Projections for 2016 - & Beyond 1 : Pharma: Your Eyes Wide Open 2 : The Top 10 Drugs In 2016 3 : Does Humira Have a Biosimilar? 4 : The Top 10 Pharmaceutical Companies 5 : Pharmaceutical Mergers in 2016: Or Not 6 : The Patent Cliff: Hanging on the Edge 7 : Goodbye Blockbusters: Hello Generics? 8 : More Generics On Tap 9 : Biosimilars: They Are Finally Here 10 : The Biosimilar Pipeline 11 : Key Drug Launches in 2016 12 : Other Key Drug Launches in 2016
Views: 3 succubus
LexCampus helps you to prepare for the Patent Agent Examination 2018. To Watch Live Webinar and clear your doubts visit https://www.lexcampus.in/webinars/ Get Micro Courses now and expertise in the topic you want visit https://www.lexcampus.in/available-courses/ The Handbook on Patent Law: https://amzn.to/2wVM6W1 (The Patents Act 1970, Patnets Rules 2003, IPAB Rules 2010 & 2011, Amendments, Cross Coded Bare Act with Cross References, Case Laws and Legislative History) Website: https://www.lexcampus.in/ Courses on Patent Agent Exam: https://www.lexcampus.in/available-courses/ Webinar schedule: https://www.lexcampus.in/webinars/ Blog: https://www.lexcampus.in/blog/ Forum for discussion: https://www.lexcampus.in/forums/ Materials for download: https://www.lexcampus.in/materials/ Podcasts: https://www.lexcampus.in/podcasts/ Also watch: Intro on Patent Law: https://www.youtube.com/watch?v=RlZK_Z6-efA Study tools: https://www.youtube.com/playlist?list=PLLMC9Q0KFmjbT42UExQL1ZWhX_UKA3OFV Also, connect with us on – LinkedIn: https://www.linkedin.com/company/lexcampus/ YouTube: https://www.lexcampus.in/ Twitter: https://twitter.com/LexCampus Facebook: https://www.facebook.com/profile.php?id=100013134169692 Instagram: https://www.instagram.com/lexcampus/ Google Plus: https://plus.google.com/u/0/100805381304069317994
Views: 509 LexCampus
THE INDIAN PATENT ACT 2005 Contents – ■ Introduction ■ Intellectual Property and its types ■ Definitions ■ History ■ features of a patent ■ Criteria for patentability and inventions not patentable in India ■ Process of patenting in India ■ Importance of patent ......................................................................................................................................................................................................................................................... Pharma Knowledge Website : http://pharmaknowledge.tk PharmaAssist App : http://tinyurl.com/PharmaAssist (For Android) https://chinmayjk97.github.io/PharmaA... (WebApp) ……………………………………………………………………………………………………………………………………………………………………………………. Other Important Information is there in this video. If you like this video, Don't Forgot to like and share. any queries and questions you can comment Music Credits – Intro Music – [Future Bass] - WRLD - Triumph [Monstercat Release] - https://www.youtube.com/watch?v=5YxVMyeIGvA Background Music – [No Copyright Music] herbal tea - Artificial.Music - Audio Library – No Copyright Music Subscribe my channel - https://www.youtube.com/c/PharmaKnowl... Thank You For Watching.
Views: 425 Pharma Knowledge
As Presented by Magna Legal Services: This short tutorial was used to explain to jurors how a patent can be issued a patent, but still infringe on other patents or be invalid.
Views: 1642 MagnaLegalServices
Manufacturing patents will play a larger role than molecule patents within the biologics development process, and these will also be a factor in terms of bringing complex products to market, argued Steven Lucio, Senior Director, Clinical Solutions and Pharmacy Program Development at Novation. This video was shot at the 2013 Academy of Managed Care Pharmacy in San Antonio, Texas.
Views: 146 Pharmacy Times TV